Targeted therapies in colorectal cancer—an integrative view by PPPM

摘要: In developed countries, colorectal cancer (CRC) is the third most common malignancy, but it second frequent cause of cancer-related death. Clinicians are still faced with numerous challenges in treatment this disease, and future approaches which target molecular features disorder will be critical for success disease setting. Genetic analyses many solid tumours have shown that up to 100 protein-encoding genes mutated. Within CRC, genetic alterations been identified a number pathways. Therefore, understanding pathology CRC may present information on potential routes also provide valuable prognostic information. This particularly pertinent molecularly targeted treatments, such as anti-vascular endothelial growth factor therapies anti-epidermal receptor (EGFR) monoclonal antibody therapy. KRAS BRAF mutations predict response anti-EGFR As EGFR can signal via phosphatidylinositol 3-kinase (PI3K) kinase pathway, there considerable interest roles members pathway (such PI3K PTEN) predicting response. combined approach new techniques allow identification these biomarkers alongside interdisciplinary advanced aid decision-making process serve guide therapeutic approaches.